Roth Capital raised the firm’s price target on Cingulate (CING) to $17 from $10 and keeps a Buy rating on the shares. The FDA’s acceptance of Cingulate’s NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth’s expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Inc’s NDA for CTx-1301 Accepted by FDA
- Cingulate announces FDA accepted for review the NDA for CTx-1301
- Cingulate Inc Approves Stock Issuance Proposal
- Cingulate Inc.’s Strategic Advances and Market Potential Reinforce Buy Rating
- Cingulate secures exclusive manufacturing partnership with Bend Bio Sciences